Oncolytics Biotech Inc T.ONC

AstraZeneca posts ADC wins at SABCS in breast cancer

[Noteable]

December 08, 2022 - In this cohort of TROPION-PanTumor01 (n=41), datopotamab deruxtecan demonstrated an objective response rate (ORR) of 27% as assessed by blinded independent central review (BICR). All responses were partial (n=11) and 56% of patients achieved stable disease (n=23). The disease control rate (DCR) was 85% and median progression-free survival (PFS) was 8.3 months (95% confidence interval [CI], 5.5-11.1). With median follow-up of 13.7 months, the median duration of response (DoR) and the median overall survival (OS) had not been reached with 59% of patients alive for more than one year. 

Approximately 70% of breast cancer tumours are considered HR-positive and HER2-low or negative. For patients with HR-positive, HER2-low or negative metastatic breast cancer that progress on or are not suitable candidates for endocrine therapy, the current standard of care is single-agent chemotherapy.

https://www.biospace.com/article/with-two-mid-phase-wins-at-sabcs-astrazeneca-continues-breast-cancer-rally/

[Noteable]

December 09, 2022 -  Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an objective response rate of 32% and a manageable safety profile in patients with metastatic TNBC in TROPION-PanTumor01 phase 1 trial. Datopotamab deruxtecan plus durvalumab (Astrazeneca's PD-1 checkpoint inhibitor) results dmonstrated an objective response rate of 73.6% in first-line treatment of

[Davepark5]

What the heck does this have to do with ONCY?  stop posting unrelated junk

[Noteable]

Very unfortunately some don't understand ADCs versus Bispecifics and both of their involvements with checkpoint inhibitors and where ONCY'S pelareorep benefits in the spectrum of immuno-oncology combination therapy. Instead they just keep barking at shadows through the window.

[Noteable]

Should read: "... where ONCY'S  pelareorep benefits them both ...."

[Noteable]

December 09, 2022 -  Astrazeneca goes head-to-head with Roche in breast cancer.  In its clinical sparring match with Kadcyla in metastatic breast cancer, Enhertu helped HER2-positive patients who'd received one prior therapy live "significantly longer," according to a SABCS press release. https://www.fiercepharma.com/pharma/sabcs-astrazeneca-writes-next

[inthno]

I read the article and a good read. Also a quick take a way is for big pharma, Roche or pfizer or someone to get a hold of pela and quickly as the bar seems to be getting set higher and higher. Still looking for a boyout vs parthership as this would take away any uncertainty down the road and thinking that something willl be done by the AGM at the latest if not earlier.

[Noteable]

Both ADCs and bispecific antibodies are increasingly seeking to be combined with immune checkpoint inhibitors which in turn can be enhanced beyond the 15-20% current effectiveness of the PD-(L)1 checkpoint inhibitors through the addition of oncolytic viruses specifically ONCY's pelareorep. PD-(L)1 checkpoint inhibitors are negatively influenced by an immunosuppressive tumor microenvironment